Search details
1.
Prediction of the Liver Safety Profile of a First-in-Class Myeloperoxidase Inhibitor Using Quantitative Systems Toxicology Modeling.
Xenobiotica
; : 1-10, 2024 Jun 14.
Article
in English
| MEDLINE | ID: mdl-38874513
2.
A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.
HIV Clin Trials
; 13(3): 119-30, 2012.
Article
in English
| MEDLINE | ID: mdl-22592092
3.
Semisynthetic Glycoconjugate Vaccine Candidates against Escherichia coli O25B Induce Functional IgG Antibodies in Mice.
JACS Au
; 2(9): 2135-2151, 2022 Sep 26.
Article
in English
| MEDLINE | ID: mdl-36186572
4.
Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
AIDS Care
; 23(11): 1500-4, 2011 Nov.
Article
in English
| MEDLINE | ID: mdl-21732894
5.
Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study.
AIDS Care
; 22(6): 677-86, 2010 Jun.
Article
in English
| MEDLINE | ID: mdl-20467943
6.
A Pharmacokinetic Bioequivalence Study Comparing Sublingual Riluzole (BHV-0223) and Oral Tablet Formulation of Riluzole in Healthy Volunteers.
Clin Pharmacol Drug Dev
; 9(4): 476-485, 2020 05.
Article
in English
| MEDLINE | ID: mdl-31610101
7.
Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: a 96-week randomized, controlled study.
Clin Infect Dis
; 48(9): 1323-6, 2009 May 01.
Article
in English
| MEDLINE | ID: mdl-19302017
8.
Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
Clin Infect Dis
; 44(11): 1484-92, 2007 Jun 01.
Article
in English
| MEDLINE | ID: mdl-17479947
9.
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
AIDS
; 20(5): 711-8, 2006 Mar 21.
Article
in English
| MEDLINE | ID: mdl-16514301
10.
Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study.
AIDS Patient Care STDS
; 26(5): 259-64, 2012 May.
Article
in English
| MEDLINE | ID: mdl-22404426
11.
Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study.
PLoS One
; 5(6): e10952, 2010 Jun 03.
Article
in English
| MEDLINE | ID: mdl-20532178
12.
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.
J Acquir Immune Defic Syndr
; 53(3): 323-32, 2010 Mar.
Article
in English
| MEDLINE | ID: mdl-20032785
13.
Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.
J Acquir Immune Defic Syndr
; 47(2): 161-7, 2008 Feb 01.
Article
in English
| MEDLINE | ID: mdl-17971713
14.
Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection.
AIDS
; 22(2): 275-9, 2008 Jan 11.
Article
in English
| MEDLINE | ID: mdl-18097230
15.
Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study
AIDS care
; 22(6): 677-686, June 2010.
Article
in English
| SES-SP, SES SP - Instituto de Infectologia Emílio Ribas, SES-SP | ID: biblio-1059245
Results
1 -
15
de 15
1
Next >
>>